These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 34036560)

  • 1. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
    Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
    Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
    Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
    Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
    Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA
    Future Oncol; 2021 Dec; 17(34):4797-4812. PubMed ID: 34521277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
    Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isatuximab-pomalidomide-dexamethasone
    Richardson PG; Perrot A; Miguel JS; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang SY; Minarik J; Cavo M; Prince HM; Macé S; Zhang R; Dubin F; Morisse MC; Anderson KC
    Haematologica; 2024 Jul; 109(7):2239-2249. PubMed ID: 38299578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
    Richardson PG; Attal M; Campana F; Le-Guennec S; Hui AM; Risse ML; Corzo K; Anderson KC
    Future Oncol; 2018 May; 14(11):1035-1047. PubMed ID: 29268619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
    Dimopoulos MA; Leleu X; Moreau P; Richardson PG; Liberati AM; Harrison SJ; Miles Prince H; Ocio EM; Assadourian S; Campana F; Malinge L; Sémiond D; van de Velde H; Yong K
    Leukemia; 2021 Feb; 35(2):562-572. PubMed ID: 32444867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
    Sunami K; Ikeda T; Huang SY; Wang MC; Koh Y; Min CK; Yeh SP; Matsumoto M; Uchiyama M; Iyama S; Shimazaki C; Lee JH; Kim K; Kaneko H; Kim JS; Lin TL; Campana F; Tada K; Iida S; Suzuki K;
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e751-e761. PubMed ID: 35641409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
    Delgado J; Zienowicz M; van Hennik PB; Moreau A; Gisselbrecht C; Enzmann H; Pignatti F
    Oncologist; 2021 Nov; 26(11):983-987. PubMed ID: 34213061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
    Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
    Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
    Decaux O; Fontan J; Perrot A; Karlin L; Touzeau C; Schulmann S; Manier S; Belhadj K; Trebouet A; Zunic P; Schiano De Colella JM; Castel B; Van De Wyngaert Z; Pica GM; Tiab M; Kuhnowski F; Bouketouche M; Rigaudeau S; Benramdane R; Tekle C; Lafore R; Gaucher M; Corre J; Leleu X
    Eur J Haematol; 2024 Sep; 113(3):290-297. PubMed ID: 38712850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.